Novavax Inc. ($NVAX) Stock Forecast: Up 5.1% Today

What is Novavax Inc.?

Novavax Inc. (NVAX) is a biotechnology company specializing in vaccine development, with a focus on infectious diseases like COVID-19. Recent market sentiment towards COVID-19 vaccine stocks has been characterized by volatility, influenced by ongoing developments and regulatory uncertainties.

Why is Novavax Inc. going up?

NVAX stock is up 5.1% on Sep 16, 2025 14:10

• Novavax (NVAX) showed a robust bullish trend despite the unfavorable situation surrounding COVID-19 vaccine stocks.
• Investors' optimism towards Novavax may stem from confidence in its vaccine candidate or other undisclosed factors driving the stock's performance.
• The positive movement could suggest an overall belief in Novavax's capabilities to overcome regulatory hurdles and achieve favorable outcomes in the future.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

https://www.zacks.com/stock/news/2751283/covid-19-vaccine-stocks-fall-on-reports-linking-shots-to-child-deaths

Trending Today

Lucid Motors Inc. ($LCID) Stock Forecast: Up 5.0% Today

Ralph Lauren Corporation ($RL) Stock Forecast: Down 0.6% Today

Astera Labs Inc ($ALAB) Stock Forecast: Up 5.1% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Down 1.5% Today

Uber Technologies Inc. ($UBER) Stock Forecast: Down 5.0% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 2.7% Today

Eaton Corporation PLC ($ETN) Stock Forecast: Down 3.3% Today

Citizens Financial Group Inc. ($CFG) Stock Forecast: Up 3.4% Today

Marathon Digital Holdings Inc. ($MARA) Stock Forecast: Up 5.3% Today

SolarEdge Technologies, Inc. ($SEDG) Stock Forecast: Up 5.7% Today

Novavax Inc. Price History

16.08.2025 - NVAX Stock was up 5.1%

• Novavax (NVAX) showed a robust bullish trend despite the unfavorable situation surrounding COVID-19 vaccine stocks.
• Investors' optimism towards Novavax may stem from confidence in its vaccine candidate or other undisclosed factors driving the stock's performance.
• The positive movement could suggest an overall belief in Novavax's capabilities to overcome regulatory hurdles and achieve favorable outcomes in the future.

01.07.2025 - NVAX Stock was down 5.0%

• The broader market experienced mixed trading today.
• Novavax closed at $6.85, showing a -2.28% shift from the previous trading day.
• Possibly disappointing news related to the company's vaccine development progress or financial performance.
• General market sentiment impacting biotech stocks negatively.
• Investors reacting to potential delays in regulatory approvals or clinical trial results.

25.06.2025 - NVAX Stock was down 8.5%

• Despite Novavax (NVAX) sharing promising results for their bird flu vaccine in primates, the stock experienced a bearish movement.
• The market might have reacted negatively due to profit-taking by investors after a recent uptrend in the stock price.
• Investors could be cautious about the company's ability to translate positive vaccine results into commercial success in the competitive pharmaceutical industry.
• The bearish movement could also be influenced by broader market factors or sector rotation, leading to a sell-off in biotech stocks despite positive news from Novavax.

02.06.2025 - NVAX Stock was up 5.4%

• NVAX stock experienced a bearish movement, decreasing by -2.15%.
• The positive market sentiment did not reflect on NVAX, suggesting company-specific factors influenced the stock's decline.
• Investors might be reacting to recent news or developments within NVAX, leading to the downward movement despite the overall bullish market trend.
• Traders should keep an eye on upcoming announcements or updates from NVAX to better understand the stock's performance in the near future.

17.05.2025 - NVAX Stock was down 5.1%

• Despite promising results indicating a robust immune response in seniors from Novavax's COVID-flu combo shot, the stock trended bearishly.
• Investor profit-taking, following a recent uptick in the stock price, may have contributed to the negative market reaction.
• Concerns about Novavax's capability to effectively launch and compete with other vaccine producers in the market might have influenced investor sentiment.
• The stock's decline could also reflect broader market trends or sector rotations affecting biotechnology companies.

28.04.2025 - NVAX Stock was down 5.1%

• The decline in NVAX stock could be attributed to heightened competition and uncertainty in the vaccine sector.
• Moderna's submission to the FDA for an enhanced COVID-19 vaccine tailored to a prevalent variant might have sparked concerns about Novavax's market position and competitiveness.
• Additionally, the retraction of Moderna's FDA submission for a COVID-flu combination vaccine could have contributed to the pessimism surrounding vaccine stocks, including NVAX.
• In general, the updates and setbacks in the vaccine field related to Moderna may have eclipsed Novavax's performance, resulting in a negative shift in NVAX stock.

06.07.2025 - NVAX Stock was up 18.4%

• Novavax saw a robust uptrend in its stock price despite prevailing market conditions.
• The decline in Novavax's stock value might be linked to the repercussions of another company's disappointing Q2 performance within the vaccine industry.
• Investors seemed optimistic about Novavax's potential to recover from the drop, which likely fueled the bullish momentum.
• The market's positive outlook on Novavax's advancements in vaccine development may have also played a role in the stock's upward movement.

06.07.2025 - NVAX Stock was up 11.3%

• Novavax (NVAX) reported impressive Q2 earnings and revenue results, surpassing estimates by a significant margin, which likely boosted investor confidence in the company's growth prospects.
• Despite Novavax's positive performance, the stock experienced a slight dip, possibly due to concerns stemming from another company's disappointing Q2 results, which had a negative impact on the entire vaccine sector.
• The broader market saw a more significant dip compared to Novavax, indicating that while there may have been some sector-specific challenges affecting the stock, Novavax managed to outperform the market on that particular day.
• Investors should keep an eye on how Novavax navigates through the challenges in the vaccine sector and capitalizes on its strong earnings to drive future growth and stock performance.

08.06.2025 - NVAX Stock was up 5.6%

• Factors contributing to the bullish movement in NVAX stock include:
• Despite a slight decline in the broader market, NVAX demonstrated resilience by closing higher, showcasing strong investor confidence.
• The potential influence of RFK Jr. in the vaccine approval process may have had a positive impact on NVAX, with the company being mentioned alongside other vaccine manufacturers such as Moderna and Pfizer.
• FDA chief Prasad's decision to restrict COVID-19 vaccine approval to specific groups could have positioned NVAX favorably, potentially increasing demand for its vaccine candidates.
• Growing macro risks like tariffs and inflation may have driven investors to seek safety in healthcare stocks like NVAX, leading to an increase in its price.

21.07.2025 - NVAX Stock was down 12.2%

• There is bearish sentiment towards Novavax in the options market, indicating pessimism among some investors.
• Novavax recently issued $225 million of convertible notes with a conversion price above the last closing price, sparking concerns about potential dilution for current shareholders.
• The market perceives the convertible notes issuance as a sign of financial strain or the need for additional funding, raising doubts about Novavax's financial stability and growth outlook.
• The convergence of bearish options market activity and the convertible notes offered at a premium conversion price likely contributed to the significant decline in Novavax's stock.

21.07.2025 - NVAX Stock was down 13.0%

• The issuance of $225 million in convertible notes by Novavax has raised concerns among investors about potential dilution, likely contributing to the recent bearish movement in the stock.
• The conversion price of the newly issued notes, set at a 27.5% premium to the last closing price, suggests the possibility of future dilution of existing shares, which has had a negative impact on the stock.
• Investor apprehension regarding Novavax's financial decisions and their potential effects on future earnings has led to a sell-off of the stock.

24.05.2025 - NVAX Stock was up 5.1%

• NVAX displayed a notable upward trend, ending at $6.41 with a +1.75% rise compared to the previous day.
• This positive momentum in NVAX could be linked to advancements in vaccine development or favorable updates on their clinical trials.
• Despite the market's decline, NVAX's performance reflects investor confidence in its future potential.
• Investors seem hopeful about NVAX's capacity to tackle global health issues, contributing to the stock's upward trajectory.